June 16, 2024Open Access

Report of case series: Correlation between pathological and radiological evaluation and clinical course of three cases of metastatic renal cell carcinoma with cytoreductive nephrectomy after combined immuno‐oncology therapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The pathologic evaluation and clinical course of cytoreductive nephrectomy after combined immuno-oncology therapy were reviewed to understand the benefits of cytoreductive nephrectomy.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Atagi et al. (Sun,) studied this question.

synapsesocial.com/papers/68e6487eb6db6435875d9950 https://doi.org/https://doi.org/10.1002/iju5.12752

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab2020 · 25 citations
2Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.2021 · 72 citations
3Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade2019 · 180 citations
4Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy2010 · 237 citations
5Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms2023 · 40 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo